相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。TIM3 comes of age as an inhibitory receptor
Yochai Wolf et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Monoclonal antibody against human Tim-3 enhances antiviral immune response
Ge Li et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2019)
Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy
Chunlin Li et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Rational design and development of a peptide inhibitor for the PD-1/PD-Ll interaction
Rebecca J. Boohaker et al.
CANCER LETTERS (2018)
IL21 Therapy Combined with PD-1 and Tim-3 Blockade Provides Enhanced NK Cell Antitumor Activity against MHC Class I-Deficient Tumors
Hyungseok Seo et al.
CANCER IMMUNOLOGY RESEARCH (2018)
TIM-3, a promising target for cancer immunotherapy
Yayi He et al.
ONCOTARGETS AND THERAPY (2018)
Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration
Ayman Oweida et al.
CLINICAL CANCER RESEARCH (2018)
Evolution of phage display technology: from discovery to application
Leila Rahbarnia et al.
JOURNAL OF DRUG TARGETING (2017)
Tim-3 and its role in regulating anti-tumor immunity
Madhumita Das et al.
IMMUNOLOGICAL REVIEWS (2017)
The immune contexture in cancer prognosis and treatment
Wolf H. Fridman et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Differential stability of therapeutic peptides with different proteolytic cleavage sites in blood, plasma and serum
Roland Boettger et al.
PLOS ONE (2017)
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
Ana C. Anderson et al.
IMMUNITY (2016)
IMMUNOTHERAPY PD-1 says goodbye, TIM-3 says hello
Diana Romero
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy
Hao-Nan Chang et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2015)
TIMgenes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity
Gordon J. Freeman et al.
IMMUNOLOGICAL REVIEWS (2015)
The immune contexture in human tumours: impact on clinical outcome
Wolf Herman Fridman et al.
NATURE REVIEWS CANCER (2012)
Anti-TIM3 Antibody Promotes T Cell IFN-γ-Mediated Antitumor Immunity and Suppresses Established Tumors
Shin Foong Ngiow et al.
CANCER RESEARCH (2011)
Double labeling and comparison of fluorescence intensity and photostability between quantum dots and FITC in oral tumors
Jian-Jiang Zhao et al.
MOLECULAR MEDICINE REPORTS (2011)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
Ting-Chao Chou
PHARMACOLOGICAL REVIEWS (2006)
Oral delivery of peptide drugs - Barriers and developments
JH Hamman et al.
BIODRUGS (2005)
Suppression of tumor growth and metastasis by a vegfr-1 antagonizing peptide identified from a phage display library
P An et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor
HT Lei et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Efficient photocyclization of dithienylethene dimer, trimer, and tetramer: Quantum yield and reaction dynamics
T Kaieda et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2002)
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
L Monney et al.
NATURE (2002)
Biodisposition of FITC-labeled aloemannan in mice
A Yagi et al.
PLANTA MEDICA (2001)
分享论文
